Amgen Inc. (AMGN) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Win.
- 2025-Q4: Total return Win; Revenue growth Win; EPS growth Win.
- 2025-Q3: Total return Lose; Revenue growth Win; EPS growth Win.
55/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 7 wins, 5 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseAMGN / S&P 3.70% / 15.20% |
LoseAMGN / S&P 9.10% / 15.00% |
LoseAMGN / S&P 31.64% / 50.40% |
| 2026-Q12/3 |
WinAMGN / S&P 8.24% / -4.33% |
LoseAMGN / S&P 9.07% / 11.30% |
WinAMGN / S&P 31.20% / 27.70% |
| 2025-Q43/3 |
WinAMGN / S&P 16.81% / 2.65% |
WinAMGN / S&P 9.95% / 9.00% |
WinAMGN / S&P 88.61% / 13.40% |
| 2025-Q32/3 |
LoseAMGN / S&P 1.89% / 8.12% |
WinAMGN / S&P 10.56% / 4.61% |
WinAMGN / S&P 65.47% / 13.45% |
| 2025-Q22/3 |
LoseAMGN / S&P -9.59% / 10.94% |
WinAMGN / S&P 12.88% / 4.83% |
WinAMGN / S&P 110.14% / 10.63% |
| 2025-Q13/3 |
WinAMGN / S&P 20.50% / -4.27% |
WinAMGN / S&P 15.56% / 4.98% |
WinAMGN / S&P 56.35% / 10.57% |
| 2024-Q41/3 |
LoseAMGN / S&P -18.46% / 2.41% |
WinAMGN / S&P 18.57% / 5.25% |
LoseAMGN / S&P -39.60% / 6.15% |
| 2024-Q31/3 |
LoseAMGN / S&P 3.84% / 5.89% |
WinAMGN / S&P 21.25% / 5.89% |
LoseAMGN / S&P -44.42% / 6.11% |
| 2024-Q22/3 |
WinAMGN / S&P 10.67% / 4.28% |
WinAMGN / S&P 16.37% / 5.38% |
LoseAMGN / S&P -60.76% / 5.12% |
| 2024-Q11/3 |
LoseAMGN / S&P -0.51% / 10.56% |
WinAMGN / S&P 12.76% / 5.71% |
LoseAMGN / S&P -52.35% / 5.59% |
| 2023-Q41/3 |
LoseAMGN / S&P 8.01% / 11.69% |
WinAMGN / S&P 7.09% / 6.81% |
LoseAMGN / S&P 3.22% / 7.78% |
| 2023-Q32/3 |
WinAMGN / S&P 22.03% / -3.27% |
LoseAMGN / S&P 1.91% / 7.52% |
WinAMGN / S&P 12.92% / -5.03% |
| 2023-Q21/3 |
LoseAMGN / S&P -7.29% / 8.74% |
LoseAMGN / S&P 0.75% / 9.50% |
WinAMGN / S&P 25.78% / -8.57% |
| 2023-Q11/3 |
LoseAMGN / S&P -7.14% / 7.50% |
LoseAMGN / S&P -0.48% / 10.77% |
WinAMGN / S&P 44.93% / -15.69% |
| 2022-Q42/3 |
WinAMGN / S&P 17.32% / 7.56% |
LoseAMGN / S&P 1.32% / 11.88% |
WinAMGN / S&P 17.57% / -17.99% |
| 2022-Q31/3 |
LoseAMGN / S&P -6.64% / -4.88% |
LoseAMGN / S&P 2.18% / 13.47% |
WinAMGN / S&P 28.19% / -1.41% |
| 2022-Q22/3 |
WinAMGN / S&P 1.42% / -16.10% |
LoseAMGN / S&P 3.53% / 13.71% |
WinAMGN / S&P 19.82% / 11.04% |
| 2022-Q11/3 |
WinAMGN / S&P 8.41% / -4.60% |
LoseAMGN / S&P 4.58% / 15.97% |
LoseAMGN / S&P -15.98% / 42.23% |
| 2021-Q40/3 |
LoseAMGN / S&P 6.68% / 11.03% |
LoseAMGN / S&P 2.18% / 15.00% |
LoseAMGN / S&P -16.40% / 96.40% |
| 2021-Q30/3 |
LoseAMGN / S&P -12.09% / 0.58% |
LoseAMGN / S&P 3.12% / 10.77% |
LoseAMGN / S&P -21.74% / 69.42% |
| 2021-Q20/3 |
LoseAMGN / S&P -1.34% / 8.55% |
LoseAMGN / S&P 4.87% / 6.58% |
LoseAMGN / S&P -19.74% / 51.81% |
| 2021-Q12/3 |
WinAMGN / S&P 9.02% / 6.17% |
WinAMGN / S&P 5.00% / -1.06% |
LoseAMGN / S&P -5.48% / 7.39% |
| 2020-Q42/3 |
LoseAMGN / S&P -8.92% / 12.15% |
WinAMGN / S&P 8.83% / -3.72% |
WinAMGN / S&P -4.42% / -33.42% |
| 2020-Q32/3 |
LoseAMGN / S&P 8.48% / 8.93% |
WinAMGN / S&P 6.80% / -2.04% |
WinAMGN / S&P -4.68% / -27.10% |
| 2020-Q22/3 |
LoseAMGN / S&P 17.13% / 20.54% |
WinAMGN / S&P 3.14% / -0.46% |
WinAMGN / S&P -2.85% / -27.11% |
| 2020-Q12/3 |
WinAMGN / S&P -15.31% / -19.60% |
LoseAMGN / S&P 0.91% / 3.47% |
WinAMGN / S&P 2.00% / -14.75% |
| 2019-Q41/3 |
WinAMGN / S&P 25.41% / 9.07% |
LoseAMGN / S&P -1.62% / 5.36% |
LoseAMGN / S&P 2.30% / 2.99% |
| 2019-Q32/3 |
WinAMGN / S&P 5.75% / 1.70% |
LoseAMGN / S&P 0.33% / 5.02% |
WinAMGN / S&P 241.10% / 0.21% |
| 2019-Q21/3 |
LoseAMGN / S&P -2.17% / 4.30% |
LoseAMGN / S&P 1.61% / 6.64% |
WinAMGN / S&P 239.25% / 8.65% |
| 2019-Q11/3 |
LoseAMGN / S&P -1.65% / 13.65% |
LoseAMGN / S&P 3.54% / 8.12% |
WinAMGN / S&P 297.78% / 14.29% |
| 2018-Q42/3 |
WinAMGN / S&P -5.43% / -13.52% |
LoseAMGN / S&P 3.93% / 9.05% |
WinAMGN / S&P 368.40% / 18.23% |
| 2018-Q31/3 |
WinAMGN / S&P 13.06% / 7.71% |
LoseAMGN / S&P 1.33% / 10.21% |
LoseAMGN / S&P -65.49% / 19.06% |
| 2018-Q21/3 |
WinAMGN / S&P 9.11% / 3.43% |
LoseAMGN / S&P 0.60% / 9.03% |
LoseAMGN / S&P -66.15% / 14.46% |
| 2018-Q10/3 |
LoseAMGN / S&P -1.23% / -0.76% |
LoseAMGN / S&P 0.05% / 7.68% |
LoseAMGN / S&P -70.14% / 12.46% |
| 2017-Q40/3 |
LoseAMGN / S&P -6.09% / 6.64% |
LoseAMGN / S&P -0.62% / 7.03% |
LoseAMGN / S&P -73.78% / 13.82% |
| 2017-Q31/3 |
WinAMGN / S&P 8.99% / 4.48% |
LoseAMGN / S&P 1.99% / 5.68% |
LoseAMGN / S&P 10.59% / 17.57% |
| 2017-Q21/3 |
WinAMGN / S&P 5.73% / 3.09% |
LoseAMGN / S&P 2.56% / 4.83% |
LoseAMGN / S&P 12.49% / 17.74% |
| 2017-Q11/3 |
WinAMGN / S&P 12.99% / 6.07% |
LoseAMGN / S&P 3.48% / 3.67% |
LoseAMGN / S&P 11.64% / 13.32% |
| 2016-Q42/3 |
LoseAMGN / S&P -11.76% / 3.82% |
WinAMGN / S&P 6.14% / 2.09% |
WinAMGN / S&P 13.25% / 7.05% |
| 2016-Q33/3 |
WinAMGN / S&P 10.27% / 3.85% |
WinAMGN / S&P 5.15% / 0.20% |
WinAMGN / S&P 19.45% / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | AMGN total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 56.10% | 20.78% |
| Annualized return | 56.10% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | AMGN total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 128.59% | 83.14% |
| Annualized return | 17.98% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | AMGN total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 246.10% | 319.30% |
| Annualized return | 13.22% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |